Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Assistant settings

journal：Cancer Research

Authors：Aditya Bardia; Sara Hurvitz; Michael F. Press; Lisa S. Wang; Nicholas P. McAndrew; David Chan; Vu Phan; Deborah Villa; Merry L. Tetef; Erin Chamberlain; Nihal Abdulla; Thomas Lomis; Laura M. Spring; Steven Applebaum; Shaker Dakhil; Brian DiCarlo; David D. Kim; Evangelia Kirimis; William E. Lawler; Aashini K. Master; Kelly McCann; Edwin Hayashi; Christine Kivork; James Chauv

Published date：2023-3-1

DOI：10.1158/1538-7445.sabcs22-gs2-03

PDF link：https://aacrjournals.org/cancerr ... TRIO-US-B-12-TALENT

Article link：http://dx.doi.org/10.1158/1538-7445.sabcs22-gs2-03

Article Source：American Association for Cancer Research (AACR)。


Remark：